Anebulo Pharmaceuticals, Inc. (ANEB) Balance Sheet
ANEB balance sheet, FY2025
June 30, 2025 · U.S. dollars$12.1M assets = $487,688 liabilities + $11.7M equity
Both columns are drawn to the same scale: what ANEB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ANEB financial health
Descriptive bands, not a rating. Fiscal FY2025.
ANEB balance sheet trends, FY2020–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $3.0MFY2020 | $12.1MFY2025 | +32.0%/yr | |
| Total liabilities | $223,865FY2020 | $487,688FY2025 | +16.9%/yr | |
| Shareholders’ equity | $2.8MFY2020 | $11.7MFY2025 | +33.0%/yr | |
| Cash & short-term investments | $3.0MFY2020 | $11.6MFY2025 | +30.9%/yr | |
| Working capital | $2.8MFY2020 | $11.7MFY2025 | +$8.9M | |
| Book value per share | $0.12FY2020 | $0.34FY2025 | +23.9%/yr | |
| Shares outstanding | 23.7MFY2020 | 33.8MFY2025 | +7.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ANEB assets
ANEB liabilities and equity
ANEB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ANEB balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $11.6M | $3.1M | $11.2M | $14.5M | $20.0M | $3.0M |
| Cash & equivalents | $11.6M | $3.1M | $11.2M | $14.5M | $20.0M | $3.0M |
| Receivables | $73,218 | $0 | $0 | $0 | $0 | $3,500 |
| Inventory | $0 | $0 | $0 | $0 | $0 | −$4 |
| Other current assets | $261,439 | $413,790 | $422,748 | $1.0M | $1.7M | $4 |
| Total current assets | $12.0M | $3.5M | $11.7M | $15.6M | $21.7M | $3.0M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $183,110 | $565,124 | $0 | $0 | $0 | $0 |
| Total assets | $12.1M | $4.1M | $11.7M | $15.6M | $21.7M | $3.0M |
| Liabilities | ||||||
| Accounts payable | $224,175 | $156,426 | $534,545 | $380,828 | $110,048 | $0 |
| Short-term debt | — | — | — | — | — | $201,286 |
| Total current liabilities | $224,175 | $260,583 | $1.1M | $512,531 | $241,633 | $223,865 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $263,513 | $0 | $0 | $0 | $0 | $3.0M |
| Total liabilities | $487,688 | $260,583 | $1.1M | $512,531 | $241,633 | $223,865 |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $41,086 | $25,934 | $25,634 | $23,345 | $23,345 | $12,000 |
| Retained earnings (deficit) | −$73.9M | −$65.4M | −$57.2M | −$45.5M | −$38.6M | −$183,137 |
| Accumulated other comprehensive income | — | — | $0 | — | $0 | −$3.0M |
| Total shareholders' equity | $11.7M | $3.8M | $10.6M | $15.1M | $21.4M | $2.8M |
| Key figures | ||||||
| Total debt | — | — | — | — | — | $201,286 |
| Net cash (debt) | — | — | — | — | — | $2.8M |
| Working capital | $11.7M | $3.2M | $10.6M | $15.1M | $21.4M | $2.8M |
| Tangible book value | $11.7M | $3.8M | $10.6M | $15.1M | $21.4M | $2.8M |
| Book value per share | $0.34 | $0.15 | $0.42 | $0.65 | $0.92 | $0.12 |
| Shares outstanding | 33.8M | 25.8M | 25.1M | 23.3M | 23.3M | 23.7M |
| Current ratio | 53.36 | 13.46 | 10.92 | 30.40 | 89.61 | 13.53 |
| Quick ratio | 52.20 | 11.87 | 10.52 | 28.39 | 82.71 | 13.53 |
| Debt / equity | — | — | — | — | — | 0.07 |
| Equity / assets | 96.0% | 93.6% | 90.8% | 96.7% | 98.9% | 92.6% |
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $9.0M | $10.4M | $11.6M | $13.3M | $15.0M | $1.4M | $3.1M | $5.1M | $6.6M | $8.5M | $11.2M | $14.2M |
| Cash & equivalents | $9.0M | $10.4M | $11.6M | $13.3M | $15.0M | $1.4M | $3.1M | $5.1M | $6.6M | $8.5M | $11.2M | $14.2M |
| Receivables | $56,783 | $9,825 | $73,218 | $0 | $30,756 | $245,362 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $175,413 | $170,771 | $261,439 | $528,034 | $366,266 | $312,940 | $413,790 | $223,676 | $171,740 | $527,306 | $422,748 | $267,801 |
| Total current assets | $9.3M | $10.5M | $12.0M | $13.8M | $15.4M | $2.0M | $3.5M | $5.4M | $6.8M | $9.0M | $11.7M | $14.4M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $148,231 | $165,670 | $183,110 | $200,548 | $445,731 | $505,427 | $565,124 | $624,820 | $684,516 | $0 | $0 | $0 |
| Total assets | $9.4M | $10.7M | $12.1M | $14.0M | $15.8M | $2.5M | $4.1M | $6.0M | $7.5M | $9.0M | $11.7M | $14.4M |
| Liabilities | ||||||||||||
| Accounts payable | $554,862 | $607,539 | $224,175 | $427,578 | $319,515 | $252,142 | $156,426 | $384,920 | $318,679 | $565,949 | $534,545 | $570,902 |
| Total current liabilities | $554,862 | $607,539 | $487,688 | $546,032 | $878,799 | $569,225 | $260,583 | $1.0M | $1.0M | $716,560 | $1.1M | $1.5M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $930,784 | $356,282 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $1.5M | $963,821 | $487,688 | $546,032 | $878,799 | $569,225 | $260,583 | $1.0M | $1.0M | $716,560 | $1.1M | $1.5M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $41,086 | $41,086 | $41,086 | $41,086 | $41,086 | $25,934 | $25,934 | $25,934 | $25,934 | $25,634 | $25,634 | $25,634 |
| Retained earnings (deficit) | −$78.0M | −$76.0M | −$73.9M | −$71.7M | −$70.1M | −$67.6M | −$65.4M | −$64.1M | −$62.4M | −$59.7M | −$57.2M | −$54.7M |
| Accumulated other comprehensive income | — | — | $0 | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Total shareholders' equity | $7.9M | $9.7M | $11.7M | $13.5M | $15.0M | $1.9M | $3.8M | $5.0M | $6.5M | $8.3M | $10.6M | $12.9M |
| Key figures | ||||||||||||
| Working capital | $8.7M | $9.9M | $11.5M | $13.3M | $14.5M | $1.4M | $3.2M | $4.4M | $5.8M | $8.3M | $10.6M | $12.9M |
| Tangible book value | $7.9M | $9.7M | $11.7M | $13.5M | $15.0M | $1.9M | $3.8M | $5.0M | $6.5M | $8.3M | $10.6M | $12.9M |
| Book value per share | $0.19 | $0.24 | $0.28 | $0.49 | $0.55 | $0.07 | $0.15 | $0.19 | $0.25 | $0.33 | $0.42 | $0.50 |
| Shares outstanding | 41.1M | 41.1M | 41.1M | 27.4M | 27.4M | 25.9M | 25.8M | 25.9M | 25.8M | 25.6M | 25.1M | 25.6M |
| Current ratio | 16.71 | 17.34 | 24.53 | 25.29 | 17.52 | 3.45 | 13.46 | 5.32 | 6.73 | 12.63 | 10.92 | 9.68 |
| Quick ratio | 16.40 | 17.06 | 23.99 | 24.32 | 17.10 | 2.90 | 11.87 | 5.09 | 6.56 | 11.89 | 10.52 | 9.50 |
| Equity / assets | 84.2% | 91.0% | 96.0% | 96.1% | 94.5% | 76.9% | 93.6% | 83.1% | 86.5% | 92.1% | 90.8% | 89.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed September 29, 2025); data from EODHD.
ANEB financial position
At the end of fiscal 2025 (June 30, 2025), Anebulo Pharmaceuticals had total assets of $12.1 million (up 198.2% from a year earlier), total liabilities of $0.5 million and shareholders' equity of $11.7 million. Its current ratio was 53.36. In the latest quarter (ended December 31, 2025) total assets were $9.4 million and equity $7.9 million.
Related: ANEB income statement, ANEB cash flow statement, ANEB key metrics. See the ANEB stock overview for the latest quote and news.
ANEB balance sheet FAQ
What are Anebulo Pharmaceuticals's total assets?
Anebulo Pharmaceuticals reported total assets of $12.1 million at the end of fiscal 2025 (June 30, 2025), compared with $4.1 million a year earlier.
How much cash does Anebulo Pharmaceuticals have?
Anebulo Pharmaceuticals held $11.6 million in cash and short-term investments at the end of fiscal 2025.
What is Anebulo Pharmaceuticals's book value?
Anebulo Pharmaceuticals's shareholders' equity (book value) was $11.7 million at the end of fiscal 2025, or $0.34 per share.
What is Anebulo Pharmaceuticals's current ratio?
Anebulo Pharmaceuticals had current assets of $12.0 million and current liabilities of $0.2 million, a current ratio of 53.36 (it can cover its short-term obligations).